Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms

Jean Leandro Dos Santos, Carolina Lanaro, Ldia Moreira Lima, Sheley Gambero, Carla Fernanda Franco-Penteado, Magna Suzana Alexandre-Moreira, Marlene Wade, Shobha Yerigenahally, Abdullah Kutlar, Steffen E Meiler, Fernando Ferreira Costa, Manchin Chung

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

A novel series of thalidomide derivatives (4a-f) designed by molecular hybridization were synthesized and evaluated in vitro and in vivo for their potential use in the oral treatment of sickle cell disease symptoms. Compounds 4a-f demonstrated analgesic, anti-inflammatory, and NO-donor properties. Compounds 4c and 4d were considered promising candidate drugs and were further evaluated in transgenic sickle cell mice to determine their capacity to reduce the levels of the proinflammatory cytokine tumor necrosis factor α (TNFα). Unlike hydroxyurea, the compounds reduced the concentrations of TNFα to levels similar to those induced with the control dexamethasone (300 μMol/kg). These compounds are novel lead drug candidates with multiple beneficial actions in the treatment of sickle cell disease symptoms and offer an alternative to hydroxyurea treatment.

Original languageEnglish (US)
Pages (from-to)5811-5819
Number of pages9
JournalJournal of Medicinal Chemistry
Volume54
Issue number16
DOIs
StatePublished - Aug 25 2011

Fingerprint

Hydroxyurea
Sickle Cell Anemia
Tumor Necrosis Factor-alpha
Pharmacology
Thalidomide
Non-Steroidal Anti-Inflammatory Agents
Pharmaceutical Preparations
Dexamethasone
Cytokines
Lead
In Vitro Techniques

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Dos Santos, J. L., Lanaro, C., Lima, L. M., Gambero, S., Franco-Penteado, C. F., Alexandre-Moreira, M. S., ... Chung, M. (2011). Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. Journal of Medicinal Chemistry, 54(16), 5811-5819. https://doi.org/10.1021/jm200531f

Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. / Dos Santos, Jean Leandro; Lanaro, Carolina; Lima, Ldia Moreira; Gambero, Sheley; Franco-Penteado, Carla Fernanda; Alexandre-Moreira, Magna Suzana; Wade, Marlene; Yerigenahally, Shobha; Kutlar, Abdullah; Meiler, Steffen E; Costa, Fernando Ferreira; Chung, Manchin.

In: Journal of Medicinal Chemistry, Vol. 54, No. 16, 25.08.2011, p. 5811-5819.

Research output: Contribution to journalArticle

Dos Santos, JL, Lanaro, C, Lima, LM, Gambero, S, Franco-Penteado, CF, Alexandre-Moreira, MS, Wade, M, Yerigenahally, S, Kutlar, A, Meiler, SE, Costa, FF & Chung, M 2011, 'Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms', Journal of Medicinal Chemistry, vol. 54, no. 16, pp. 5811-5819. https://doi.org/10.1021/jm200531f
Dos Santos JL, Lanaro C, Lima LM, Gambero S, Franco-Penteado CF, Alexandre-Moreira MS et al. Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. Journal of Medicinal Chemistry. 2011 Aug 25;54(16):5811-5819. https://doi.org/10.1021/jm200531f
Dos Santos, Jean Leandro ; Lanaro, Carolina ; Lima, Ldia Moreira ; Gambero, Sheley ; Franco-Penteado, Carla Fernanda ; Alexandre-Moreira, Magna Suzana ; Wade, Marlene ; Yerigenahally, Shobha ; Kutlar, Abdullah ; Meiler, Steffen E ; Costa, Fernando Ferreira ; Chung, Manchin. / Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. In: Journal of Medicinal Chemistry. 2011 ; Vol. 54, No. 16. pp. 5811-5819.
@article{d10cd606f56341b398047162631659dd,
title = "Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms",
abstract = "A novel series of thalidomide derivatives (4a-f) designed by molecular hybridization were synthesized and evaluated in vitro and in vivo for their potential use in the oral treatment of sickle cell disease symptoms. Compounds 4a-f demonstrated analgesic, anti-inflammatory, and NO-donor properties. Compounds 4c and 4d were considered promising candidate drugs and were further evaluated in transgenic sickle cell mice to determine their capacity to reduce the levels of the proinflammatory cytokine tumor necrosis factor α (TNFα). Unlike hydroxyurea, the compounds reduced the concentrations of TNFα to levels similar to those induced with the control dexamethasone (300 μMol/kg). These compounds are novel lead drug candidates with multiple beneficial actions in the treatment of sickle cell disease symptoms and offer an alternative to hydroxyurea treatment.",
author = "{Dos Santos}, {Jean Leandro} and Carolina Lanaro and Lima, {Ldia Moreira} and Sheley Gambero and Franco-Penteado, {Carla Fernanda} and Alexandre-Moreira, {Magna Suzana} and Marlene Wade and Shobha Yerigenahally and Abdullah Kutlar and Meiler, {Steffen E} and Costa, {Fernando Ferreira} and Manchin Chung",
year = "2011",
month = "8",
day = "25",
doi = "10.1021/jm200531f",
language = "English (US)",
volume = "54",
pages = "5811--5819",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "16",

}

TY - JOUR

T1 - Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms

AU - Dos Santos, Jean Leandro

AU - Lanaro, Carolina

AU - Lima, Ldia Moreira

AU - Gambero, Sheley

AU - Franco-Penteado, Carla Fernanda

AU - Alexandre-Moreira, Magna Suzana

AU - Wade, Marlene

AU - Yerigenahally, Shobha

AU - Kutlar, Abdullah

AU - Meiler, Steffen E

AU - Costa, Fernando Ferreira

AU - Chung, Manchin

PY - 2011/8/25

Y1 - 2011/8/25

N2 - A novel series of thalidomide derivatives (4a-f) designed by molecular hybridization were synthesized and evaluated in vitro and in vivo for their potential use in the oral treatment of sickle cell disease symptoms. Compounds 4a-f demonstrated analgesic, anti-inflammatory, and NO-donor properties. Compounds 4c and 4d were considered promising candidate drugs and were further evaluated in transgenic sickle cell mice to determine their capacity to reduce the levels of the proinflammatory cytokine tumor necrosis factor α (TNFα). Unlike hydroxyurea, the compounds reduced the concentrations of TNFα to levels similar to those induced with the control dexamethasone (300 μMol/kg). These compounds are novel lead drug candidates with multiple beneficial actions in the treatment of sickle cell disease symptoms and offer an alternative to hydroxyurea treatment.

AB - A novel series of thalidomide derivatives (4a-f) designed by molecular hybridization were synthesized and evaluated in vitro and in vivo for their potential use in the oral treatment of sickle cell disease symptoms. Compounds 4a-f demonstrated analgesic, anti-inflammatory, and NO-donor properties. Compounds 4c and 4d were considered promising candidate drugs and were further evaluated in transgenic sickle cell mice to determine their capacity to reduce the levels of the proinflammatory cytokine tumor necrosis factor α (TNFα). Unlike hydroxyurea, the compounds reduced the concentrations of TNFα to levels similar to those induced with the control dexamethasone (300 μMol/kg). These compounds are novel lead drug candidates with multiple beneficial actions in the treatment of sickle cell disease symptoms and offer an alternative to hydroxyurea treatment.

UR - http://www.scopus.com/inward/record.url?scp=80051880495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051880495&partnerID=8YFLogxK

U2 - 10.1021/jm200531f

DO - 10.1021/jm200531f

M3 - Article

VL - 54

SP - 5811

EP - 5819

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 16

ER -